Get started
Author

Yoshimichi Koutake

Association between pretreatment neutrophil‐to‐lymphocyte ratio and immune‐related adverse events due to immune checkpoint inhibitors in patients with non‐small cell lung cancer
2021 · Airi Fujimoto, Gouji Toyokawa, et al. · Thoracic Cancer · 38
Risk factors for delayed chemotherapy-induced nausea and vomiting with low-emetic-risk chemotherapy: a prospective, observational, multicenter study
2018 · Toshinobu Hayashi, Mototsugu Shimokawa, et al. · Cancer Management and Research · 24
PDF
A prospective, observational, multicenter study on risk factors and prophylaxis for low emetic risk chemotherapy-induced nausea and vomiting
2017 · Toshinobu Hayashi, Mototsugu Shimokawa, et al. · Supportive Care in Cancer · 16
Risk factors indicating immune-related adverse events with combination chemotherapy with immune checkpoint inhibitors and platinum agents in patients with non-small cell lung cancer: a multicenter retrospective study
2023 · Airi Fujimoto, Yoshimichi Koutake, et al. · Cancer Immunology Immunotherapy · 14
PDF
Influence of proton pump inhibitors and H2-receptor antagonists on the efficacy and safety of dasatinib in chronic myeloid leukemia patients
2020 · Yoshimichi Koutake, Jun Taniguchi, et al. · International Journal of Hematology · 6
Survey of Hospital Pharmacists' Experience and Awareness Regarding Clinical Research
2020 · Yoshimichi Koutake, Yosei Kawamata, et al. · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) · 4
PDF
Effects of meropenem supply restriction: A multicenter retrospective study
2024 · Yoshimichi Koutake, Yoji Nagasaki, et al. · Journal of Infection and Chemotherapy · 3
Teicoplanin total trough concentration and adverse effects in patients with hypoalbuminemia
2025 · Hirofumi Oishi, Yoshimichi Koutake, et al. · Journal of Infection and Chemotherapy · 1
Effect of antiemetic corticosteroids on the development of immune-related adverse events caused by chemoimmunotherapy: a multicenter retrospective study
2025 · Airi Fujimoto, Yoshimichi Koutake, et al. · Supportive Care in Cancer · 1
Predictors for the Clinical Efficacy of Tramadol for Cancer Pain
2023 · Yoshimichi Koutake, Airi Fujimoto, et al. · American Journal of Hospice and Palliative Medicine® · 1
PDF
[Efficacy of Primary Prophylaxis with Pegfilgrastim after Docetaxel for Castration-Resistant Prostate Cancer].
2019 · Yoshimichi Koutake, Yasufumi Tsurusaki, et al. · PubMed · 1
Preventive Effects of SGLT2 Inhibitors on Cisplatin-Induced Nephrotoxicity in Patients with Solid Tumors and Diabetes: A Multicenter, Retrospective Cohort Study
2026 · Masaya Kanda, Toshinobu Hayashi, et al. · Research Square
Comparative efficacy of carbapenem and non-carbapenem empirical therapy for Klebsiella pneumoniae Bacteremia
2026 · Yoshimichi Koutake, Hirofumi Oishi, et al. · Journal of Infection and Chemotherapy
Multiple-day dexamethasone for controlling delayed chemotherapy-induced nausea and vomiting with low-emetic-risk chemotherapy
2026 · Akari Yamashita, Toshinobu Hayashi, et al. · BMC Cancer
Correction: Risk factors indicating immune-related adverse events with combination chemotherapy with immune checkpoint inhibitors and platinum agents in patients with non-small cell lung cancer: a multicenter retrospective study
2024 · Airi Fujimoto, Yoshimichi Koutake, et al. · Cancer Immunology Immunotherapy
PDF
がん化学療法における支持療法と薬物間相互作用に関する研究
2023 · Koutake, Yoshimichi, 高武, 嘉道 · Institutional Repositories DataBase (IRDB)
Evaluation of risk factors predicting delayed chemotherapy-induced nausea and vomiting in patients receiving low emetic risk chemotherapy (LEC): A prospective, observational, multicenter study
2017 · Toshinobu Hayashi, Mototsugu Shimokawa, et al. · Annals of Oncology
Low emetic chemotherapy–induced nausea and vomiting: a prospective, multicenter, observational study
2015 · Toshinobu Hayashi, Mototsugu Shimokawa, et al. · Annals of Oncology
PDF
Works count: 18
Citation count: 109
H-index: 5
I10-index: 4
Year
Topic
Type